Fujirebio & Randox in cancer assay deal:
This article was originally published in Clinica
Fujirebio Diagnostics (FDI) is collaborating with UK firm Randox Laboratories on the development of cancer diagnostic assays that will employ FDI's cancer marker antibodies and Randox' automated biochip array technology. Crumlin, Northern Ireland-based Randox' array technology permits the simultaneous determination of a panel of diagnostic markers from just a single patient sample. Multiplexing - using several biomarkers together - may help detect disease at an earlier, more treatable stage, said FDI, of Malvern, Pennsylvania firm (see Clinica No 1018, p 17).
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.